CA2363605A1 - Suppresseur de proliferation cellulaire induit par androgene et ses utilisations - Google Patents

Suppresseur de proliferation cellulaire induit par androgene et ses utilisations Download PDF

Info

Publication number
CA2363605A1
CA2363605A1 CA002363605A CA2363605A CA2363605A1 CA 2363605 A1 CA2363605 A1 CA 2363605A1 CA 002363605 A CA002363605 A CA 002363605A CA 2363605 A CA2363605 A CA 2363605A CA 2363605 A1 CA2363605 A1 CA 2363605A1
Authority
CA
Canada
Prior art keywords
nucleic acid
polypeptide
cell
protein
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002363605A
Other languages
English (en)
Inventor
Ana M. Soto
Carlos Sonnenschein
Peter Geck
Jozsef Szelei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2363605A1 publication Critical patent/CA2363605A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des nouvelles séquences d'acides nucléiques du gène AS3, des polypeptides AS3, des anticorps AS3, et des méthodes de modulation de la prolifération cellulaire et de détection de composés qui modulent ladite prolifération. L'invention concerne également des méthodes diagnostiques et thérapeutiques faisant appel à ces compositions.
CA002363605A 1999-02-24 2000-02-24 Suppresseur de proliferation cellulaire induit par androgene et ses utilisations Abandoned CA2363605A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12146199P 1999-02-24 1999-02-24
US60/121,461 1999-02-24
PCT/US2000/004732 WO2000050454A1 (fr) 1999-02-24 2000-02-24 Suppresseur de proliferation cellulaire induit par androgene et ses utilisations

Publications (1)

Publication Number Publication Date
CA2363605A1 true CA2363605A1 (fr) 2000-08-31

Family

ID=22396883

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002363605A Abandoned CA2363605A1 (fr) 1999-02-24 2000-02-24 Suppresseur de proliferation cellulaire induit par androgene et ses utilisations

Country Status (5)

Country Link
EP (1) EP1165605A1 (fr)
AU (1) AU2884200A (fr)
CA (1) CA2363605A1 (fr)
HK (1) HK1042905A1 (fr)
WO (1) WO2000050454A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
JP4744140B2 (ja) * 2002-05-10 2011-08-10 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド アンドロゲン調節性ｐｍｅｐａ１遺伝子および癌細胞増殖を抑制するための同遺伝子の使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031531A1 (fr) * 1996-03-01 1997-09-04 Merck & Co., Inc. Agents anti-androgenes et leurs procedes d'identification

Also Published As

Publication number Publication date
HK1042905A1 (zh) 2002-08-30
AU2884200A (en) 2000-09-14
WO2000050454A1 (fr) 2000-08-31
EP1165605A1 (fr) 2002-01-02

Similar Documents

Publication Publication Date Title
JP2006166917A (ja) Ｃｒｓｐタンパク質、それらをコードする核酸分子およびその用途
JP2002531069A (ja) タンパク質のカプサイシン／バニロイド受容体ファミリーの新規メンバー及びそれらの使用
US7268218B2 (en) Cardiovascular system associated protein kinase 3 (CSAPK-3) antibodies
US6423494B1 (en) DR6 and uses thereof
US6225085B1 (en) LRSG protein and nucleic acid molecules and uses therefor
US6872811B1 (en) HRPCa9 and HRPCa10 nucleic acids and polypeptides
WO1999041412A1 (fr) Nouveau gene npg-1 differentiellement exprime dans les tumeurs de la prostate
JP2002516079A (ja) 新規分泌型および膜会合型タンパク質ならびにそのための用途
WO2002038767A2 (fr) Nouvelles proteine recepteur couplee a une proteine g et molecules d'acides nucleiques, et utilisations associees
US6994992B1 (en) Androgen-induced suppressor of cell proliferation and uses thereof
CA2363605A1 (fr) Suppresseur de proliferation cellulaire induit par androgene et ses utilisations
US6756212B1 (en) Isolated proteins and nucleic acid molecules having homology to the NIP2 protein and uses thereof
US7632660B2 (en) Lymphoma associated molecules and uses therefor
WO2001000878A9 (fr) Nouveau membre de la famille des facteurs de croissance des cellules endotheliales vasculaires et son utilisation
US20020004193A1 (en) Novel MP-7 protein and nucleic acid molecules and uses therefor
US6485921B1 (en) UBCLP and uses thereof
US6870040B1 (en) Nucleic acid sequence encoding lymphoma associated molecule BAL
US20020065223A1 (en) 33358, a novel human ankyrin family member and uses thereof
US20020123094A1 (en) 57250, a novel human sugar transporter family member and uses thereof
CA2348758A1 (fr) Molecules associees au lymphome et leurs utilisations
US20020115185A1 (en) Neuronal cell death associated molecules and uses therefor
US20020086982A1 (en) Novel EBI-3-ALT protein and nucleic acid molecules and uses therefor
WO2000017236A2 (fr) Proteines reliees a l'apoptose et utilisations associees
WO2000039277A2 (fr) Acides nucleiques codant pour ndsp et polypeptides ndsp

Legal Events

Date Code Title Description
FZDE Dead